Joseph Monahan - 01 Mar 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, Attorney-in-fact
Issuer symbol
ACRS
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 17:11:06 UTC
Previous filing
11 Feb 2022
Next filing
14 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +13,750 +16% 101,051 01 Mar 2022 Direct F1
transaction ACRS Common Stock Options Exercise +50,000 +49% 151,051 01 Mar 2022 Direct F1
transaction ACRS Common Stock Options Exercise +12,500 +8.3% 163,551 02 Mar 2022 Direct F1
holding ACRS Common Stock 193 01 Mar 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +153,100 $0.000000 153,100 01 Mar 2022 Common Stock 153,100 $14.94 Direct F2
transaction ACRS Restricted stock units Award $0 +43,700 $0.000000 43,700 01 Mar 2022 Common Stock 43,700 Direct F1, F3
transaction ACRS Restricted stock units Options Exercise $0 -13,750 -50% $0.000000 13,750 01 Mar 2022 Common Stock 13,750 Direct F1, F4
transaction ACRS Restricted stock units Options Exercise $0 -50,000 -25% $0.000000 150,000 01 Mar 2022 Common Stock 50,000 Direct F1, F5
transaction ACRS Restricted stock units Options Exercise $0 -12,500 -33% $0.000000 25,000 02 Mar 2022 Common Stock 12,500 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F3 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F5 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.
F6 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.